Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04416568 · ClinicalTrials.gov registry record · Phase 2
Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers
A Phase 2 study of Atypical Teratoid/Rhabdoid Tumor and Malignant Rhabdoid Tumor, sponsored by Dana-Farber Cancer Institute.
- Active
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
- 8
- Study locations
NCT04416568: Active Phase 2 study of Atypical Teratoid/Rhabdoid Tumor and Malignant Rhabdoid Tumor, sponsored by Dana-Farber Cancer Institute.
NCT04416568 is a Phase 2 study of Atypical Teratoid/Rhabdoid Tumor and Malignant Rhabdoid Tumor that is active but no longer recruiting, run by Dana-Farber Cancer Institute. The registered enrollment target is 45 participants, below the 83-participant average among 9 other Atypical Teratoid/Rhabdoid Tumor trials with a reported enrollment target (46% lower). The trial reports 8 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04416568, a Phase 2 study of Atypical Teratoid/Rhabdoid Tumor and Malignant Rhabdoid Tumor, is active but no longer recruiting, sponsored by Dana-Farber Cancer Institute.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
- 8
- Study locations
Study Summary
This clinical trial is studying two immunotherapy drugs (nivolumab and ipilimumab) given together as a possible treatment for INI1-negative tumors.
Primary Outcome
Based on Response Evaluation in Solid Tumors (RECIST) version 1.1
Conditions Studied
Interventions
- DRUG Nivolumab
- DRUG Ipilimumab
Study Locations (8)
Massachusetts
- Massachusetts General Hospital - Boston
- Boston Children's Hospital - Boston
- Dana-Farber Cancer Institute - Boston
Georgia
- Children's Healthcare of Atlanta-Egleston - Atlanta
- Children's Healthcare of Atlanta-Scottish Rite - Atlanta
California
- UCSF Benioff Children's Hospital - San Francisco
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
Texas
- Texas Children's Hospital - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2020-08-14 |
| Est. Completion | 2026-06 |
| Phase | Phase 2 |
What the registry record for NCT04416568 still lists
NCT04416568 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 83-participant average among 9 other Atypical Teratoid/Rhabdoid Tumor trials with a reported enrollment target (46% lower).
The record links to 7 conditions, with Atypical Teratoid/Rhabdoid Tumor appearing as the primary indexed condition, and to 2 interventions - of which Nivolumab is the first listed.
NCT04416568 lists 8 locations in 5 states (Massachusetts, Georgia, California).
Frequently Asked Questions
What is clinical trial NCT04416568 about?
NCT04416568 is a clinical study titled "Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers". This clinical trial is studying two immunotherapy drugs (nivolumab and ipilimumab) given together as a possible treatment for INI1-negative tumors.
What is the current status of trial NCT04416568?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2020-08-14. Estimated completion is 2026-06.
What conditions does trial NCT04416568 study?
This clinical trial studies the following conditions: Atypical Teratoid/Rhabdoid Tumor, Malignant Rhabdoid Tumor, Epithelioid Sarcoma, Rhabdoid Tumor of the Kidney, Chordoma (Poorly Differentiated or De-differentiated).
What interventions are being tested in trial NCT04416568?
The interventions under investigation include: Nivolumab (DRUG), Ipilimumab (DRUG).
Who is sponsoring clinical trial NCT04416568?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04416568 being conducted?
This trial has 8 study locations across California, Georgia, Massachusetts, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atypical Teratoid/Rhabdoid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04416568's enrollment target sits among peer trials
45 7th of 9 higher than 3 of 9 other Atypical Teratoid/Rhabdoid Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Atypical Teratoid/Rhabdoid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors
ACTIVE NOT RECRUITING · Phase 2
-
Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors
RECRUITING · Phase 1
-
Loc3CAR: Locoregional Delivery of B7-H3-CAR T Cells for Pediatric Patients With Primary CNS Tumors
RECRUITING · Phase 1
-
Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas
RECRUITING · Phase 1
-
Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors
RECRUITING · Phase 1
-
HER2-specific CAR T Cell Locoregional Immunotherapy for HER2-positive Recurrent/Refractory Pediatric CNS Tumors
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI